Pulmonary hypertension associated with left heart disease

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 5, 2013, Pages 665-680

  Adir, Yochai ^a   Amir, Offer ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

heart failure; left heart disease; pulmonary hypertension; valvular disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ELASTASE; ENDOTHELIN; MATRIX METALLOPROTEINASE; NATRIURETIC FACTOR; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; SILDENAFIL; TEZOSENTAN;

ARTICLE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG MEGADOSE; DYSPNEA; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART VALVE SURGERY; HUMAN; LOW DRUG DOSE; LUNG HEMODYNAMICS; LUNG PRESSURE; LUNG VASCULAR RESISTANCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; ENDOTHELIUM, VASCULAR; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MITRAL VALVE STENOSIS; PHOSPHODIESTERASE 5 INHIBITORS; PROGNOSIS; PROSTAGLANDINS I; PULMONARY CIRCULATION; RECEPTORS, ENDOTHELIN; RHEUMATIC HEART DISEASE; VASCULAR RESISTANCE;

EID: 84884214740     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1356490     Document Type: Article

References (169)

1. McLaughlin V. V., Archer S. L., Badesch D. B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol: 2009; 53 17 1573 1619
2. Galiè N., Hoeper M. M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J: 2009; 34 6 1219 1263
3. Gheorghiade M., Filippatos G., De Luca L., Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med: 2006; 119 12 01 S3 S10
4. Lucas C., Johnson W., Hamilton M. A., et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J: 2000; 140 6 840 847
5. Oudiz R. J. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med: 2007; 28 1 233 241, x
6. Rich S., Rabinovitch M. Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation: 2008; 118 21 2190 2199
7. Haddad F., Kudelko K., Mercier O., Vrtovec B., Zamanian R. T., de Jesus Perez V. Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. Prog Cardiovasc Dis: 2011; 54 2 154 167
8. Shapiro B. P., Nishimura R. A., McGoon M. D., et al. Diagnostic dilemmas: diastolic heart failure causing pulmonary hypertension and pulmonary hypertension causing diastolic dysfunction.Adv. Pulmon Hypertens: 2006; 5 13 20
9. Hoeper M. M., Barberà J. A., Channick R. N., et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol: 2009; 54 1 (Suppl): S85 S96
10. Kay J. M., Edwards F. R. Ultrastructure of the alveolar-capillary wall in mitral stenosis. J Pathol: 1973; 111 4 239 245
11. Lee Y-S. Electron microscopic studies on the alveolar-capillary barrier in the patients of chronic pulmonary edema. Jpn Circ J: 1979; 43 10 945 954
12. Townsley M. I., Fu Z., Mathieu-Costello O., West J. B. Pulmonary microvascular permeability. Responses to high vascular pressure after induction of pacing-induced heart failure in dogs. Circ Res: 1995; 77 2 317 325
13. Drake R. E., Doursout M. F. Pulmonary edema and elevated left atrial pressure: four hours and beyond. News Physiol Sci: 2002; 17 223 226
14. Wagenvoort C., Wagenvoort N. Pathology of Pulmonary Hypertension. 2nd ed. New York, NY John Wiley & Sons: 1977
15. Delgado J. F., Conde E., Sánchez V., et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail: 2005; 7 6 1011 1016
16. Du L., Sullivan C. C., Chu D., et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med: 2003; 348 6 500 509
17. Moraes D. L., Colucci W. S., Givertz M. M. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation: 2000; 102 14 1718 1723
18. Porter T. R., Taylor D. O., Cycan A., et al. Endothelium-dependent pulmonary artery responses in chronic heart failure: influence of pulmonary hypertension. J Am Coll Cardiol: 1993; 22 5 1418 1424
19. Cooper C. J., Jevnikar F. W., Walsh T., Dickinson J., Mouhaffel A., Selwyn A. P. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol: 1998; 82 5 609 614
20. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature: 1988; 332 6163 411 415
21. Galié N., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res: 2004; 61 2 227 237
22. Cody R. J., Haas G. J., Binkley P. F., Capers Q., Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation: 1992; 85 2 504 509
23. Rodeheffer R. J., Lerman A., Heublein D. M., Burnett J. C. Jr. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc: 1992; 67 8 719 724
24. Tsutamoto T., Wada A., Maeda Y., Adachi T., Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol: 1994; 23 6 1427 1433
25. Fukuroda T., Kobayashi M., Ozaki S., et al. Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol: 1994; 76 5 1976 1982
26. Dupuis J., Goresky C. A., Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol: 1996; 81 4 1510 1515
27. Drazner M. H., Hamilton M. A., Fonarow G., Creaser J., Flavell C., Stevenson L. W. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant: 1999; 18 11 1126 1132
28. Drazner M. H., Prasad A., Ayers C., et al. The relationship of right- and left-sided filling pressures in patients with heart failure and a preserved ejection fraction. Circ Heart Fail: 2010; 3 2 202 206
29. Zener J. C., Hancock E. W., Shumway N. E., Harrison D. C. Regression of extreme pulmonary hypertension after mitral valve surgery. Am J Cardiol: 1972; 30 8 820 826
30. Levine M. J., Weinstein J. S., Diver D. J., et al. Progressive improvement in pulmonary vascular resistance after percutaneous mitral valvuloplasty. Circulation: 1989; 79 5 1061 1067
31. Fawzy M. E., Hassan W., Stefadouros M., Moursi M., El Shaer F., Chaudhary M. A. Prevalence and fate of severe pulmonary hypertension in 559 consecutive patients with severe rheumatic mitral stenosis undergoing mitral balloon valvotomy. J Heart Valve Dis: 2004; 13 6 942 947, discussion 947-948
32. Costard-Jäckle A., Fowler M. B. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol: 1992; 19 1 48 54
33. Leung C. C., Moondra V., Catherwood E., Andrus B. W. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol: 2010; 106 2 284 286
34. Thenappan T., Shah S. J., Gomberg-Maitland M., et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail: 2011; 4 3 257 265
35. Buchbinder N., Ganz W. Hemodynamic monitoring: invasive techniques. Anesthesiology: 1976; 45 2 146 155
36. Chemla D., Castelain V., Hervé P., Lecarpentier Y., Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J: 2002; 20 5 1314 1331
37. Senni M., Redfield M. M. Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol: 2001; 38 5 1277 1282
38. Nootens M., Wolfkiel C. J., Chomka E. V., Rich S. Understanding right and left ventricular systolic function and interactions at rest and with exercise in primary pulmonary hypertension. Am J Cardiol: 1995; 75 5 374 377
39. Butler J., Chomsky D. B., Wilson J. R. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol: 1999; 34 6 1802 1806
40. Franciosa J. A., Baker B. J., Seth L. Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricular failure. Am Heart J: 1985; 110 4 807 813
41. Givertz M. M., Hare J. M., Loh E., Gauthier D. F., Colucci W. S. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol: 1996; 28 7 1775 1780
42. Ha J. W., Choi D., Park S., et al. Determinants of exercise-induced pulmonary hypertension in patients with normal left ventricular ejection fraction. Heart: 2009; 95 6 490 494
43. Shim C. Y., Kim S. A., Choi D., et al. Clinical outcomes of exercise-induced pulmonary hypertension in subjects with preserved left ventricular ejection fraction: implication of an increase in left ventricular filling pressure during exercise. Heart: 2011; 97 17 1417 1424
44. Maeder M. T., Thompson B. R., Brunner-La Rocca H. P., Kaye D. M. Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll Cardiol: 2010; 56 11 855 863
45. Borlaug B. A., Nishimura R. A., Sorajja P., Lam C. S., Redfield M. M. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail: 2010; 3 5 588 595
46. Di Salvo T. G., Mathier M., Semigran M. J., Dec G. W. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol: 1995; 25 5 1143 1153
47. Reindl I., Wernecke K. D., Opitz C., et al. Impaired ventilatory efficiency in chronic heart failure: possible role of pulmonary vasoconstriction. Am Heart J: 1998; 136 5 778 785
48. Methvin A. B., Owens A. T., Emmi A. G., et al. Ventilatory inefficiency reflects right ventricular dysfunction in systolic heart failure. Chest: 2011; 139 3 617 625
49. Lewis G. D., Shah R. V., Pappagianopolas P. P., Systrom D. M., Semigran M. J. Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. Circ Heart Fail: 2008; 1 4 227 233
50. Lewis G. D., Murphy R. M., Shah R. V., et al. Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes. Circ Heart Fail: 2011; 4 3 276 285
51. Croft J. B., Giles W. H., Pollard R. A., Keenan N. L., Casper M. L., Anda R. F. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med: 1999; 159 5 505 510
52. Davis R. C., Hobbs F. D., Kenkre J. E., et al. Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study. BMJ: 2002; 325 7373 1156
53. Aurigemma G. P., Gaasch W. H. Clinical practice. Diastolic heart failure. N Engl J Med: 2004; 351 11 1097 1105
54. Zafrir B., Paz H., Wolff R., et al. Mortality rates and modes of death in heart failure patients with reduced versus preserved systolic function. Eur J Intern Med: 2011; 22 1 53 56
55. Ghio S., Gavazzi A., Campana C., et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol: 2001; 37 1 183 188
56. Klapholz M., Maurer M., Lowe A. M., et al. New York Heart Failure Consortium. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol: 2004; 43 8 1432 1438
57. Lam C. S., Roger V. L., Rodeheffer R. J., Borlaug B. A., Enders F. T., Redfield M. M. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol: 2009; 53 13 1119 1126
58. Neuman Y., Kotliroff A., Bental T., Siegel R. J., David D., Lishner M. Pulmonary artery pressure and diastolic dysfunction in normal left ventricular systolic function. Int J Cardiol: 2008; 127 2 174 178
59. Owan T. E., Hodge D. O., Herges R. M., Jacobsen S. J., Roger V. L., Redfield M. M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med: 2006; 355 3 251 259
60. Amir O., Paz H., Rogowski O., et al. Serum oxidative stress level correlates with clinical parameters in chronic systolic heart failure patients. Clin Cardiol: 2009; 32 4 199 203
61. Rogowski O., Shnizer S., Wolff R., Lewis B. S., Amir O. Increased serum levels of oxidative stress are associated with hospital readmissions due to acute heart failure. Cardiology: 2011; 118 1 33 37
62. Amir O., Rogowski O., David M., Lahat N., Wolff R., Lewis B. S. Circulating interleukin-10: association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha. Isr Med Assoc J: 2010; 12 3 158 162
63. Paulus W. J., Tschöpe C., Sanderson J. E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J: 2007; 28 20 2539 2550
64. Amir R. E., Amir O., Paz H., et al. Genotype-phenotype associations between chymase and angiotensin-converting enzyme gene polymorphisms in chronic systolic heart failure patients. Genet Med: 2008; 10 8 593 598
65. Amir O., Amir R. E., Paz H., Mor R., Sagiv M., Lewis B. S. Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. Am J Cardiol: 2008; 102 3 326 329
66. Goren Y., Kushnir M., Zafrir B., Tabak S., Lewis B. S., Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail: 2012; 14 2 147 154
67. McMurray J. J., Adamopoulos S., Anker S. D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail: 2012; 14 8 803 869
68. Hogg K., Swedberg K., McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol: 2004; 43 3 317 327
69. McMurray J. J., Carson P. E., Komajda M., et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail: 2008; 10 2 149 156
70. Dwyer E. M., Asif M., Ippolito T., Gillespie M. Role of hypertension, diabetes, obesity, and race in the development of symptomatic myocardial dysfunction in a predominantly minority population with normal coronary arteries. Am Heart J: 2000; 139 2 Pt 1 297 304
71. de las Fuentes L., Brown A. L., Mathews S. J., et al. Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur Heart J: 2007; 28 5 553 559
72. Robbins I. M., Newman J. H., Johnson R. F., et al. Association of the metabolic syndrome with pulmonary venous hypertension. Chest: 2009; 136 1 31 36
73. Kawaguchi M., Hay I., Fetics B., Kass D. A. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation: 2003; 107 5 714 720
74. Tedford R. J., Hassoun P. M., Mathai S. C., et al. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation: 2012; 125 2 289 297
75. Walston A., Peter R. H., Morris J. J., Kong Y., Behar V. S. Clinical implications of pulmonary hypertension in mitral stenosis. Am J Cardiol: 1973; 32 5 650 655
76. Bonow R. O., Carabello B. A., Chatterjee K., et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol: 2006; 48 3 e1 e148
77. Alexopoulos D., Lazzam C., Borrico S., Fiedler L., Ambrose J. A. Isolated chronic mitral regurgitation with preserved systolic left ventricular function and severe pulmonary hypertension. J Am Coll Cardiol: 1989; 14 2 319 322
78. Silver K., Aurigemma G., Krendel S., Barry N., Ockene I., Alpert J. Pulmonary artery hypertension in severe aortic stenosis: incidence and mechanism. Am Heart J: 1993; 125 1 146 150
79. Naidoo D. P., Mitha A. S., Vythilingum S., Chetty S. Pulmonary hypertension in aortic regurgitation: early surgical outcome. Q J Med: 1991; 80 291 589 595
80. Angeja B. G., Grossman W. Evaluation and management of diastolic heart failure. Circulation: 2003; 107 5 659 663
81. Rich S., Dantzker D. R., Ayres S. M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med: 1987; 107 2 216 223
82. Baker B. J., Wilen M. M., Boyd C. M., Dinh H., Franciosa J. A. Relation of right ventricular ejection fraction to exercise capacity in chronic left ventricular failure. Am J Cardiol: 1984; 54 6 596 599
83. Borlaug B. A., Nishimura R. A., Sorajja P., Lam C. S., Redfield M. M. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail: 2010; 3 5 588 595
84. Januzzi J. L. Jr. Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure. Cleve Clin J Med: 2006; 73 2 149 152, 155-157
85. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J: 2008; 29 19 2388 2442
86. Nagueh S. F., Middleton K. J., Kopelen H. A., Zoghbi W. A., Quiñones M. A. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol: 1997; 30 6 1527 1533
87. Stojnic B. B., Brecker S. J., Xiao H. B., Helmy S. M., Mbaissouroum M., Gibson D. G. Left ventricular filling characteristics in pulmonary hypertension: a new mode of ventricular interaction. Br Heart J: 1992; 68 1 16 20
88. Moustapha A., Kaushik V., Diaz S., Kang S. H., Barasch E. Echocardiographic evaluation of left-ventricular diastolic function in patients with chronic pulmonary hypertension. Cardiology: 2001; 95 2 96 100
89. Little W. C., Badke F. R., O'Rourke R. A. Effect of right ventricular pressure on the end-diastolic left ventricular pressure-volume relationship before and after chronic right ventricular pressure overload in dogs without pericardia. Circ Res: 1984; 54 6 719 730
90. Sunagawa K., Maughan W., Weisfeldt M., et al. Effect of systolic transseptal pressure on septal elastance and ventricular cross-talk. [abstract] Circulation: 1981; 64 (Suppl IV): 180
91. Lam C. S. Heart failure with preserved ejection fraction: invasive solution to diagnostic confusion? J Am Coll Cardiol: 2010; 55 16 1711 1712
92. Walston A. II, Kendall M. E. Comparison of pulmonary wedge and left atrial pressure in man. Am Heart J: 1973; 86 2 159 164
93. Fishman A. P. A century of pulmonary hemodynamics. Am J Respir Crit Care Med: 2004; 170 2 109 113
94. de Groote P., Millaire A., Foucher-Hossein C., et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol: 1998; 32 4 948 954
95. Polak J. F., Holman B. L., Wynne J., Colucci W. S. Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. J Am Coll Cardiol: 1983; 2 2 217 224
96. Meluzin J., Spinarová L., Hude P., et al. Combined right ventricular systolic and diastolic dysfunction represents a strong determinant of poor prognosis in patients with symptomatic heart failure. Int J Cardiol: 2005; 105 2 164 173
97. Bursi F., McNallan S. M., Redfield M. M., et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol: 2012; 59 3 222 231
98. Szwejkowski B. R., Elder D. H., Shearer F., et al. Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study. Eur J Heart Fail: 2012; 14 2 162 167
99. La Vecchia L., Zanolla L., Varotto L., et al. Reduced right ventricular ejection fraction as a marker for idiopathic dilated cardiomyopathy compared with ischemic left ventricular dysfunction. Am Heart J: 2001; 142 1 181 189
100. Cappola T. P., Felker G. M., Kao W. H., Hare J. M., Baughman K. L., Kasper E. K. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation: 2002; 105 14 1663 1668
101. Leeman M., Van Cutsem M., Vachiéry J. L., Antoine M., Leclerc J. L. Determinants of right ventricular failure after heart transplantation. Acta Cardiol: 1996; 51 5 441 449
102. Addonizio L. J., Gersony W. M., Robbins R. C., et al. Elevated pulmonary vascular resistance and cardiac transplantation. Circulation: 1987; 76 5 Pt 2 V52 V55
103. Murali S., Kormos R. L., Uretsky B. F., et al. Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience. Am Heart J: 1993; 126 4 896 904
104. Kirklin J. K., Naftel D. C., Kirklin J. W., Blackstone E. H., White-Williams C., Bourge R. C. Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant: 1988; 7 5 331 336
105. Tenderich G., Koerner M. M., Stuettgen B., et al. Does preexisting elevated pulmonary vascular resistance (transpulmonary gradient > 15 mm Hg or > 5 wood) predict early and long-term results after orthotopic heart transplantation? Transplant Proc: 1998; 30 4 1130 1131
106. Erickson K. W., Costanzo-Nordin M. R., O'Sullivan E. J., et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant: 1990; 9 5 526 537
107. Natale M. E., Piña I. L. Evaluation of pulmonary hypertension in heart transplant candidates. Curr Opin Cardiol: 2003; 18 2 136 140
108. Cimato T. R., Jessup M. Recipient selection in cardiac transplantation: contraindications and risk factors for mortality. J Heart Lung Transplant: 2002; 21 11 1161 1173
109. Klotz S., Deng M. C., Hanafy D., et al. Reversible pulmonary hypertension in heart transplant candidates-pretransplant evaluation and outcome after orthotopic heart transplantation. Eur J Heart Fail: 2003; 5 5 645 653
110. Villanueva F. S., Murali S., Uretsky B. F., et al. Resolution of severe pulmonary hypertension after heterotopic cardiac transplantation. J Am Coll Cardiol: 1989; 14 5 1239 1243
111. Rabinovitch M. Pulmonary hypertension: pathophysiology as a basis for clinical decision making. J Heart Lung Transplant: 1999; 18 11 1041 1053
112. Kjaergaard J., Akkan D., Iversen K. K., et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol: 2007; 99 8 1146 1150
113. Hart S. A., Krasuski R. A., Wang A., Kisslo K., Harrison J. K., Bashore T. M. Pulmonary hypertension and elevated transpulmonary gradient in patients with mitral stenosis. J Heart Valve Dis: 2010; 19 6 708 715
114. Ader R., Chatterjee K., Ports T., Brundage B., Hiramatsu B., Parmley W. Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation: 1980; 61 5 931 937
115. Regitz-Zagrosek V., Neuss M., Fleck E. Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects. Eur Heart J: 1995; 16 (Suppl N): 86 91
116. Silke B. Haemodynamic impact of diuretic therapy in chronic heart failure. Cardiology: 1994; 84 02 115 123
117. Micha T. Maeder, MD, David M. Kaye Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol: 2009; 53 905 918
118. Yip G. W., Frenneaux M., Sanderson J. E. Heart failure with a normal ejection fraction: new developments. Heart: 2009; 95 19 1549 1552
119. Zile M. R., Brutsaert D. L. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation: 2002; 105 11 1387 1393
120. Zile M. R., Brutsaert D. L. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation: 2002; 105 12 1503 1508
121. Yusuf S., Pfeffer M. A., Swedberg K., et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet: 2003; 362 9386 777 781
122. Sueta C. A., Gheorghiade M., Adams K. F. Jr., et al. Epoprostenol Multicenter Research Group Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Am J Cardiol: 1995; 75 3 34A 43A
123. Montalescot G., Drobinski G., Meurin P., et al. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol: 1998; 82 6 749 755
124. Califf R. M., Adams K. F., McKenna W. J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J: 1997; 134 1 44 54
125. Patrono C., Pugliese F., Ciabattoni G., et al. Evidence for a direct stimulatory effect of prostacyclin on renin release in man. J Clin Invest: 1982; 69 1 231 239
126. Sablotzki A., Czeslick E., Schubert S., et al. Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension. Can J Anaesth: 2002; 49 10 1076 1080
127. Radovancevic B., Vrtovec B., Thomas C. D., et al. Nitric oxide versus prostaglandin E1 for reduction of pulmonary hypertension in heart transplant candidates. J Heart Lung Transplant: 2005; 24 6 690 695
128. Kiowski W., Sütsch G., Hunziker P., et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet: 1995; 346 8977 732 736
129. Ooi H., Colucci W. S., Givertz M. M. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Circulation: 2002; 106 13 1618 1621
130. Zolk O., Quattek J., Seeland U., El-Armouche A., Eschenhagen T., Böhm M. Activation of the cardiac endothelin system in left ventricular hypertrophy before onset of heart failure in TG(mREN2)27 rats. Cardiovasc Res: 2002; 53 2 363 371
131. Miyauchi T., Fujimori A., Maeda S., et al. Chronic administration of an endothelin-A receptor antagonist improves exercise capacity in rats with myocardial infarction-induced congestive heart failure. J Cardiovasc Pharmacol: 2004; 44 01 S64 S67
132. Torre-Amione G., Young J. B., Durand J-B., et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation: 2001; 103 7 973 980
133. Torre-Amione G., Young J. B., Colucci W. S., et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol: 2003; 42 1 140 147
134. Sütsch G., Kiowski W., Yan X. W., et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation: 1998; 98 21 2262 2268
135. Packer M., McMurray J., Massie B. M., et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail: 2005; 11 1 12 20
136. Packer M. Effects of the endothelin antagonist bosentan on the morbidity and mortality in patients with chronic heart failure. Results of the ENABLE 1 and 2 trial program. Presented at the College of Cardiology Meeting, March: 2002
137. Lüscher T. F., Enseleit F., Pacher R., et al. Heart Failure ET(A) Receptor Blockade Trial. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation: 2002; 106 21 2666 2672
138. Anand I., McMurray J., Cohn J. N., et al. EARTH investigators. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet: 2004; 364 9431 347 354
139. Teerlink J. R. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Card Fail: 2002; 8 3 124 127
140. Perez-Villa F., Farrero M., Cardona M., et al. Bosentan in heart transplantation candidates with severe pulmonary hypertension: efficacy, safety and outcome after transplantation. Clin Transplant: 2013; 27 1 25 31
141. Katz S. D., Hryniewicz K., Hriljac I., et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation: 2005; 111 3 310 314
142. Katz S. D., Schwarz M., Yuen J., LeJemtel T. H. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation: 1993; 88 1 55 61
143. Koelling T. M., Kirmse M., Di Salvo T. G., Dec G. W., Zapol W. M., Semigran M. J. Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction. Am J Cardiol: 1998; 81 12 1494 1497
144. Guazzi M. Sildenafil and phosphodiesterase-5 inhibitors for heart failure. Curr Heart Fail Rep: 2008; 5 2 110 114
145. Guazzi M., Vicenzi M., Arena R. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. Eur J Heart Fail: 2012; 14 1 82 90
146. Kass D. A., Champion H. C., Beavo J. A. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res: 2007; 101 11 1084 1095
147. Takimoto E., Champion H. C., Li M., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med: 2005; 11 2 214 222
148. Das A., Xi L., Kukreja R. C. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem: 2005; 280 13 12944 12955
149. Fisher P. W., Salloum F., Das A., Hyder H., Kukreja R. C. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation: 2005; 111 13 1601 1610
150. Pérez N. G., Piaggio M. R., Ennis I. L., et al. Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction. Hypertension: 2007; 49 5 1095 1103
151. Guazzi M., Tumminello G., Di Marco F., Fiorentini C., Guazzi M. D. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol: 2004; 44 12 2339 2348
152. Lewis G. D., Lachmann J., Camuso J., et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation: 2007; 115 1 59 66
153. Guazzi M., Samaja M., Arena R., Vicenzi M., Guazzi M. D. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol: 2007; 50 22 2136 2144
154. Lewis G. D., Shah R., Shahzad K., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation: 2007; 116 14 1555 1562
155. Zakliczynski M., Maruszewski M., Pyka L., et al. Effectiveness and safety of treatment with sildenafil for secondary pulmonary hypertension in heart transplant candidates. Transplant Proc: 2007; 39 9 2856 2858
156. Tedford R. J., Hemnes A. R., Russell S. D., et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail: 2008; 1 4 213 219
157. Behling A., Rohde L. E., Colombo F. C., Goldraich L. A., Stein R., Clausell N. Effects of 5′-phosphodiesterase four-week long inhibition with
158. Packer M., Carver J. R., Rodeheffer R. J., et al. The PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med: 1991; 325 21 1468 1475
159. Guazzi M., Vicenzi M., Arena R., Guazzi M. D. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation: 2011; 124 2 164 174
160. Guazzi M., Arena R., Ascione A., Piepoli M., Guazzi M. D.; Gruppo di Studio Fisiologia dell'Esercizio, Cardiologia dello Sport e Riabilitazione Cardiovascolare of the Italian Society of Cardiology. Exercise oscillatory breathing and increased ventilation to carbon dioxide production slope in heart failure: an unfavorable combination with high prognostic value. Am Heart J: 2007; 153 5 859 867
161. Guazzi M., Raimondo R., Vicenzi M., et al. Exercise oscillatory ventilation may predict sudden cardiac death in heart failure patients. J Am Coll Cardiol: 2007; 50 4 299 308
162. Sun X. G., Hansen J. E., Beshai J. F., Wasserman K. Oscillatory breathing and exercise gas exchange abnormalities prognosticate early mortality and morbidity in heart failure. J Am Coll Cardiol: 2010; 55 17 1814 1823
163. Rosenhek R., Rader F., Klaar U., et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation: 2006; 113 18 2238 2244
164. Fattouch K., Sbraga F., Bianco G., et al. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg: 2005; 20 2 171 176
165. Riedel B. The pathophysiology and management of perioperative pulmonary hypertension with specific emphasis on the period following cardiac surgery. Int Anesthesiol Clin: 1999; 37 2 55 79
166. Dávila-Román V. G., Waggoner A. D., Hopkins W. E., Barzilai B. Right ventricular dysfunction in low output syndrome after cardiac operations: assessment by transesophageal echocardiography. Ann Thorac Surg: 1995; 60 4 1081 1086
167. Rex S., Schaelte G., Metzelder S., et al. Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. Acta Anaesthesiol Scand: 2008; 52 1 65 72
168. Malouf J. F., Enriquez-Sarano M., Pellikka P. A., et al. Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. J Am Coll Cardiol: 2002; 40 4 789 795
169. Khot U. N., Novaro G. M., Popović Z. B., et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med: 2003; 348 18 1756 1763